Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

461 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Pinho MC, Polaskova P, Kalpathy-Cramer J, Jennings D, Emblem KE, Jain RK, Rosen BR, Wen PY, Sorensen AG, Batchelor TT, Gerstner ER. Pinho MC, et al. Among authors: rosen br. Oncologist. 2014 Jan;19(1):75-81. doi: 10.1634/theoncologist.2013-0101. Epub 2013 Dec 5. Oncologist. 2014. PMID: 24309981 Free PMC article. Clinical Trial.
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Batchelor TT, et al. Among authors: rosen br. Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19059-64. doi: 10.1073/pnas.1318022110. Epub 2013 Nov 4. Proc Natl Acad Sci U S A. 2013. PMID: 24190997 Free PMC article. Clinical Trial.
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival.
Andronesi OC, Esmaeili M, Borra RJH, Emblem K, Gerstner ER, Pinho MC, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Ivy SP, Wen PY, Duda DG, Jain R, Rosen BR, Sorensen GA, Batchelor TT. Andronesi OC, et al. Among authors: rosen br. NPJ Precis Oncol. 2017;1:20. doi: 10.1038/s41698-017-0020-3. Epub 2017 Jun 12. NPJ Precis Oncol. 2017. PMID: 29202103 Free PMC article.
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER. Ly KI, et al. Among authors: rosen br. Sci Rep. 2018 Nov 20;8(1):17062. doi: 10.1038/s41598-018-34820-x. Sci Rep. 2018. PMID: 30459364 Free PMC article.
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
Kalpathy-Cramer J, Chandra V, Da X, Ou Y, Emblem KE, Muzikansky A, Cai X, Douw L, Evans JG, Dietrich J, Chi AS, Wen PY, Stufflebeam S, Rosen B, Duda DG, Jain RK, Batchelor TT, Gerstner ER. Kalpathy-Cramer J, et al. J Neurooncol. 2017 Feb;131(3):603-610. doi: 10.1007/s11060-016-2332-5. Epub 2016 Nov 16. J Neurooncol. 2017. PMID: 27853960 Free PMC article. Clinical Trial.
Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma.
Gerstner ER, Emblem KE, Chang K, Vakulenko-Lagun B, Yen YF, Beers AL, Dietrich J, Plotkin SR, Catana C, Hooker JM, Duda DG, Rosen B, Kalpathy-Cramer J, Jain RK, Batchelor T. Gerstner ER, et al. Clin Cancer Res. 2020 Jan 1;26(1):206-212. doi: 10.1158/1078-0432.CCR-19-1739. Epub 2019 Sep 26. Clin Cancer Res. 2020. PMID: 31558474 Free PMC article.
461 results